Botox advertising alert
May 2, 2013
THE Therapeutic Goods
Administration has issued new
advice for cosmetic clinics over
their promotional practices,
which in some cases has seen
S4 medications such as Botox
advertised to consumers.
An update on the TGA website
states that “some health
professionals and cosmetic/beauty
clinics are advertising, to the
general public, goods or substances
that are designated ‘prescriptiononly’
items”.
Products cited include hyaluronic
acid (Restylane, Perlane, Dermalive,
Juvederm); hyaluronan and sodium
hyaluronate (Hylaform); collagen
(Zyderm, Zyplast, Cosmoplast
and Cosmoderm); polylactic
acid (Newfill, Nufill, Sculptra);
polyacrylamide (Aquamid); and
botulinum toxin (Botox, Dysport).
“These products are generally
administered for the purpose of
temporarily removing/reducing
lines on the face, around the eyes,
forehead, lips and neck,” according
to the TGA statement.
The TGA noted that these
substances are listed in Schedule
4 of the current Poisons Standard
and “should be available from a
pharmacist on prescription”.
To enable the continued
promotion of the services while
also complying with the regulatory
advertising requirements for
therapeutic goods, the TGA has
advised of a range of “acceptable
general phrases” which may be
used in advertising, including
‘cosmetic injections’, ‘anti-wrinkle
injections/treatments’, ‘injections/
treatments for lips’, ‘injections to
enhance pouting of the lips’ and
‘injections which reduce the depth
of fine lines’.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 May 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 May 13
